OTCMKTS:BIOVF Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis $27.21 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$27.21▼$27.2150-Day Range$25.20▼$27.5452-Week Range$18.35▼$27.79VolumeN/AAverage Volume353 shsMarket CapitalizationN/AP/E Ratio45.35Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Swedish Orphan Biovitrum AB (publ) alerts: Email Address Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.Read More BIOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOVF Stock News HeadlinesJuly 26 at 6:24 PM | msn.comMirum Pharma gains amid report of approach from Swedish Orphan BiovitrumJuly 22, 2024 | uk.finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (BIOVF)July 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 19, 2024 | markets.businessinsider.comSwedish Orphan Biovitrum AB (0MTD) Receives a Buy from RBC CapitalJuly 19, 2024 | americanbankingnews.comSwedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Issues Earnings ResultsJuly 18, 2024 | americanbankingnews.comSwedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest UpdateMay 24, 2024 | finance.yahoo.comSobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation SyndromeMay 24, 2024 | finance.yahoo.comSobi to present new myelofibrosis data at the ASCO 2024 Annual MeetingJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 8, 2024 | finance.yahoo.comSobi has completed SEK 3 billion senior bond issueMay 6, 2024 | uk.finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (SOBI.ST)April 27, 2024 | seekingalpha.comSwedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call TranscriptApril 26, 2024 | finance.yahoo.comSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia AApril 25, 2024 | msn.comSwedish Orphan Biovitrum AB reports Q1 resultsApril 25, 2024 | finance.yahoo.comSobi Q1 2024 report: Strong sales reflecting the strength of the portfolioApril 24, 2024 | markets.businessinsider.comSwedish Orphan Biovitrum AB earnings: here's what to expectApril 4, 2024 | prnewswire.comNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)April 2, 2024 | finance.yahoo.comSobi publishes Annual and sustainability report for 2023See More Headlines Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/16/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CUSIPN/A CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,772Year Founded2001Profitability EPS (Most Recent Fiscal Year)$0.60 Trailing P/E Ratio45.35 Forward P/E RatioN/A P/E GrowthN/ANet Income$227.17 million Net Margins9.10% Pretax Margin11.26% Return on Equity7.00% Return on Assets3.26% Debt Debt-to-Equity Ratio0.32 Current Ratio0.71 Quick Ratio0.50 Sales & Book Value Annual Sales$2.09 billion Price / SalesN/A Cash Flow$1.90 per share Price / Cash Flow14.29 Book Value$10.82 per share Price / Book2.51Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.59 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Guido Oelkers (Age 59)CEO & President Comp: $25.82MMr. Henrik Stenqvist (Age 57)Chief Financial Officer Mr. Torbjörn Hallberg (Age 55)General Counsel & Head of Legal Affairs Mr. Daniel Rankin (Age 44)Head of Strategy & Corporate Development Ms. Lena Bjurner (Age 56)Head of Human Resources Mr. Armin Reininger M.D. (Age 67)Ph.D., Senior Scientific & Medical Advisor Mr. Norbert Oppitz (Age 57)Head of International Mr. Sofiane Fahmy (Age 52)Head of Europe Mr. Duane H. Barnes (Age 64)Head of North America Mr. Mahmood Ladha (Age 60)Head of Strategic Transformation Operations More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW1933 IndustriesOTCMKTS:TGIFF3SBioOTCMKTS:TRSBF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFView All Competitors BIOVF Stock Analysis - Frequently Asked Questions How have BIOVF shares performed this year? Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the beginning of the year. Since then, BIOVF stock has increased by 3.7% and is now trading at $27.21. View the best growth stocks for 2024 here. How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter? Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its quarterly earnings data on Tuesday, July, 16th. The company reported $0.07 earnings per share for the quarter. The firm earned $509.05 million during the quarter. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 7.00% and a net margin of 9.10%. How do I buy shares of Swedish Orphan Biovitrum AB (publ)? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOVF) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Swedish Orphan Biovitrum AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
